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Down Syndrome (DS) is a genetic disorder caused by trisomy of human chromosome 21 (Hsa21). DS 
phenotypes include cognitive impairment, craniofacial abnormalities, low muscle tone, and skeletal 
deficiencies. The Ts65Dn mouse model exhibits similar phenotypes as found in humans with DS, including 
deficits in skeletal bone. Over-expression of DYRK1A, a serine-threonine kinase encoded on Hsa21, has 
been linked to deficiencies in DS bone homeostasis. Epigallocatechin-3-gallate (EGCG), an aromatic 
polyphenol found in green tea (GT), is a known inhibitor of Dyrk1a activity. Normalization of Dyrk1a 
activity by EGCG may have the potential to regulate bone homeostasis, by increasing bone mineral density 
(BMD) and bone strength. We hypothesized that EGCG obtained from different vendors would differ in 
stability as well as success in ameliorating skeletal deficiencies. EGCG from different sources was 
subjected to degradation analysis because of its low bioavailability due to strong antioxidative 
characteristics. We also hypothesized that phosphoric acid would stabilize EGCG and prevent breakdown 
in an aqueous solution. We performed High Performance Liquid Chromatography–Mass 
Spectrometry (HPLC-MS) on EGCG from different sources to determine the amount of EGCG degradation 
in solution. Our analyses showed differential stability in EGCG from different sources or with phosphoric 
acid. We chose EGCG from three sources to test the hypothesis that these compounds would have differing 
effects treating bone phenotypes associated with DS.  Three-week-old Ts65Dn and control male mice were 
treated with EGCG for three weeks. At six weeks of age, mice were sacrificed and femurs were extracted. 
BMD, bone strength, as well as architecture of the femur were assessed.  Our results indicate that EGCG 
from different sources has diverse effects on the correction of bone phenotypes associated with DS.  Our 
work is important to understand how EGCG from different sources may affect DS phenotypes as the EGCG 
is translated to human use.   
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